GlassScriptPhysician profile
J Michael Watts
NPI 1205889581
$14,041.70
in general payments reported to CMS, 2019-2025
52 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $1,679 · 2021: $1,964 · 2022: $2,371 · 2023: $2,851 · 2024: $2,242 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,698 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,698.39 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,865.81 | 2019-2025 | Hizentra |
| Ucb, INC. | $1,722.15 | 2019-2024 | Briviact, Rystiggo |
| Abbvie INC. | $1,376.98 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Sk Life Science, INC. | $941.05 | 2020-2025 | |
| Acorda Therapeutics, INC | $656.85 | 2020-2024 | Inbrija |
| Lundbeck LLC | $626.71 | 2020-2025 | Vyepti |
| Lilly USA, LLC | $458.61 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $388.84 | 2022-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $359.53 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $347.41 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $323.06 | 2019-2021 | |
| Argenx US, INC. | $305.87 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Biogen, INC. | $284.94 | 2021-2025 | Leqembi |
| Merz Pharmaceuticals, LLC | $282.53 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Alexion Pharmaceuticals, INC. | $276.03 | 2019-2025 | Ultomiris |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.